A Phase 1 Multicenter Open-label Dose-Exploration and Dose-Expansion Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors

Brief description of study

The purpose of this study is to obtain initial information on the safety and tolerability (good or bad effects) of a drug given by mouth, called AMG 650. This study will also look at what doses of AMG 650 are safe for people who take it, study how the drug interacts with your type of cancer, and to determine potential biomarkers (measurable indicators in the body) for patient selection. The study drug AMG 650 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s19-00741
ClinicalTrials.gov Identifier: NCT04293094
Principal Investigator: Sylvia Adams.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.